EFFICACY AND SAFETY OF PEMETREXED AS SECOND-LINE TREATMENT IN ELDERLY PATIENTS (PTS) WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A RETROSPECTIVE ANALYSIS

被引：0
|
作者：
Passaro, A. [1 ]
Pochesci, A. [1 ]
Palleschi, M. [1 ]
Pellegrino, A. [2 ]
Fabbri, M. A. [3 ]
Urbano, F. [1 ]
Gentile, V. [1 ]
Manai, C. [1 ]
Pavese, I. [2 ]
Cortesi, E. [1 ]
机构：
[1] Univ Roma La Sapienza, Div Med Oncol, Rome, Italy
[2] San Pietro Fatebenefratelli Hosp, Dept Oncol, Rome, Italy
[3] Osped Belcolle, Dept Med Oncol, Viterbo, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S70 / S70
页数：1
相关论文
共 50 条
  • [1] TOLERANCE AND EFFICACY OF CHEMOTHERAPY WITH PLATINUM AND PEMETREXED IN ELDERLY PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Leprieur, Etienne Giroux
    Labrune, Sylvie
    Giraud, Violaine
    Gendry, Thierry
    Cobarzan, Daniel
    Chinet, Thierry
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1285 - S1286
  • [2] Efficiency of nivolumab in the treatment of second-line advanced non-squamous non-small cell lung cancer (NSCLC) in Spain
    Gonzalez, P.
    Ortega-Joaquin, N.
    Provencio Pulla, M.
    Garrido, C.
    Echave, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Efficacy and safety of bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer (NSCLC)
    Tassinari, D.
    Drudi, F.
    Carloni, F.
    Nicoletti, S.
    Possenti, C.
    Santelmo, C.
    Lazzari, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Pemetrexed as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): Efficacy and correlation with molecular markers
    Blasco, A.
    Sirera, R.
    Terrasa, J.
    Provencio, M.
    Guillen, C.
    Maestu, I.
    de las Penas, R.
    Bover, I.
    Berdiel, M.
    de Aguirre, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] ERLOTINIB (ERL) VERSUS PEMETREXED (MTA) AS SECOND-LINE TREATMENT FOR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSNSCLC): EFFICACY AND SAFETY DATA
    Zugazagoitia, J.
    Puente, J.
    Hernandez, S.
    Gonzalez-Larriba, J. L.
    Sanz, J.
    Manzano, A.
    Diaz-Rubio, E.
    ANNALS OF ONCOLOGY, 2012, 23 : 438 - 439
  • [6] Pemetrexed versus vinorelbine treatment of advanced non-squamous non-small cell lung cancer in elderly patients
    Chen, Yongshun
    Wen, Qinglian
    Liu, Hao
    Ao, Rui
    Wu, Xiaoyuan
    Guo, Leiming
    Wang, Wen
    He, Chunyu
    Wang, Jianhua
    MOLECULAR AND CLINICAL ONCOLOGY, 2013, 1 (03) : 553 - 557
  • [7] Clinical Study of Pemetrexed as the First-line Treatment in Elderly Patients with Advanced Non-squamous Non-small Cell Lung Cancer
    Pu Xiaolin
    Wang Jun
    Li Wei
    Lu Binbin
    Wang Zhaoxia
    Yang Min
    Fan Weifei
    JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2013, 1 (04): : 205 - 209
  • [8] A retrospective study of maintenance pemetrexed in advanced non-squamous non-small cell lung cancer
    Oguh, L.
    Ranatunge, D.
    Lind, M.
    Ukadhyay, S.
    El-Mahdawi, N.
    LUNG CANCER, 2018, 115 : S30 - S30
  • [9] The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC)
    Ding, Lingyu
    Liu, Kejun
    Jiang, Zhelong
    Chen, Qi
    Zhou, Ningning
    Liang, Ying
    Gao, Hongfei
    Hong, Xiangchan
    Wu, Haiying
    TUMOR BIOLOGY, 2015, 36 (04) : 2491 - 2499
  • [10] Efficacy and safety of second-line immunotherapy in patients with advanced non-small cell lung cancer
    Sanchez Escudero, Laura
    Cobelas Cartagena, Stephanie S.
    Sanchez Esperilla, Maria
    Bayo, Juan L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345